BetterLife Pharma（BETR.F）株式概要バイオテクノロジー企業であるBetterLife Pharma Inc.は、主にカナダで精神障害治療用化合物の開発に注力している。 詳細BETR.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去5年間の収益は年間55.5%増加しました。 リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きいマイナスの株主資本 収益が 100 万ドル未満 ( CA$0 )意味のある時価総額がありません ( $7M )すべてのリスクチェックを見るBETR.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.046該当なし内在価値ディスカウントEst. Revenue$PastFuture-36m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.1AdvancedSet Fair ValueView all narrativesBetterLife Pharma Inc. 競合他社InMed PharmaceuticalsSymbol: NasdaqCM:INMMarket cap: US$7.7mProcessa PharmaceuticalsSymbol: NasdaqCM:PCSAMarket cap: US$7.0mCNS PharmaceuticalsSymbol: NasdaqCM:CNSPMarket cap: US$7.9mcbdMDSymbol: NYSEAM:YCBDMarket cap: US$8.0m価格と性能株価の高値、安値、推移の概要BetterLife Pharma過去の株価現在の株価US$0.04652週高値US$0.08852週安値US$0.028ベータ0.541ヶ月の変化-7.01%3ヶ月変化2.86%1年変化-43.75%3年間の変化-21.44%5年間の変化-86.13%IPOからの変化-99.90%最新ニュースお知らせ • Apr 18BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in fundingOn April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering.お知らせ • Apr 09BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in fundingBetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws.お知らせ • May 28Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026.お知らせ • May 19BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025.お知らせ • May 15BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric DisordersBetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases.お知らせ • Mar 31BetterLife Pharma Inc. Appoints Steven Sangha to its Board of DirectorsBetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.最新情報をもっと見るRecent updatesお知らせ • Apr 18BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in fundingOn April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering.お知らせ • Apr 09BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in fundingBetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws.お知らせ • May 28Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026.お知らせ • May 19BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025.お知らせ • May 15BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric DisordersBetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases.お知らせ • Mar 31BetterLife Pharma Inc. Appoints Steven Sangha to its Board of DirectorsBetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.お知らせ • Nov 27BetterLife Pharma Inc. Obtains Cardiac Safety Data for BETR-001BetterLife Pharma Inc. announced it has completed one of its IND-enabling cardiac safety studies of BETR-001. These GLP in vitro studies demonstrated that BETR-001 has minimal impact on the human ether- a-go-go-related gene (hERG) channel, an important ion channel for cardiac functioning.お知らせ • Oct 23BetterLife Pharma Inc. Obtains Favourable Genotoxicity Data for Oral BETR-001BetterLife Pharma Inc. announced it has completed one of its IND-enabling genotoxicity studies of BETR-001. The studies demonstrated that oral BETR-001, even at very high doses, does not show any evidence of bone marrow toxicity or mutagenic (DNA mutation) and clastogenic (chromosome damage) activities. The GLP genotoxicity studies conducted on BETR-001 included in vitro bacterial reverse mutation assay, in vitro micronucleus test, and in vivo micronucleus test in male and female rats. These studies are a critical component of the safety assessment required by the U.S. Food and Drug Administration (FDA) and needed for entry into clinical trials.お知らせ • Aug 29BetterLife Pharma Inc. announced that it expects to receive CAD 1.1 million in fundingBetterLife Pharma Inc announced a non brokered private placement offering of 7,333,333 units issued at a price of CAD 0.15 per unit for gross proceeds CAD 1,099,999.95 on August 29, 2024. Each unit consisting of one common share in the capital of the Company and one full common share purchase warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD 0.20 for up to two years following the date of the closing of the Private Placement. The close is subject to the receipt of all necessary regulatory and other approvals which will be announced as soon as it has been completed.お知らせ • Jul 03BetterLife Pharma Inc. announced that it has received CAD 0.175 million in fundingOn July 2, 2024, BetterLife Pharma Inc. closed the transaction.お知らせ • May 15BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001BetterLife Pharma Inc. announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials did not show any significant cardiopulmonary pharmacological safety issues in animals. Cardiopulmonary safety (also known as telemetry) studies investigate the effect of a drug in animals using surgically implanted transmitters to assess blood pressure, electrocardiography (ECG), lung respiration, body temperature, and general activity level. The BETR-001 cardiopulmonary study found no BETR-001 related effects on ECG intervals, respiratory parameters, core body temperature, or activity levels.お知らせ • May 03BetterLife Pharma Inc. Advances BETR-001 IND-Enabling StudiesBetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024.お知らせ • Apr 13BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024.お知らせ • Mar 05BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in fundingBetterLife Pharma Inc. announced a private placement to issue convertible debentures for the gross proceeds of CAD 100,000 on March 4, 2024. The transaction will include participation from individual investor such as Ahmad Doroudian for CAD 100,000.お知らせ • Mar 04BetterLife Pharma Inc. announced that it has received CAD 0.065 million in fundingBetterLife Pharma Inc. announced a private placement to issue 10% convertible debentures for the gross proceeds of CAD 65,000 on March 4, 2024. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on August 31, 2026. The debentures bear 10% interest rate and matures on February 28, 2026.お知らせ • Jan 02BetterLife Pharma Inc. announced that it has received CAD 0.3 million in fundingBetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 10% convertible debentures for principal[al amount of CAD 300,000 on January 2, 2024. The convertible debenture interest rate of 10%, will mature on June 30, 2025. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on December 31, 2025. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of CAD 125,000 principal amount of convertible debentures under the Offering.お知らせ • Dec 18BetterLife Pharma Inc. announced that it has received CAD 0.2 million in fundingBetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 2,000,000 units at an issue price of CAD 0.10 per Unit for aggregate gross proceeds of CAD 200,000 on December 18, 2023. Each Unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.10 at any time up to 24 months from the closing of the Offering. The Units sold pursuant to the Offering will be subject to a four month hold period pursuant to applicable Canadian securities laws. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of 1,000,000 Units under the Offering.お知らせ • Dec 01Us Patent and Trademark Office Publishes Betterlife’S Comprehensive Patent for Betr-001 and Other Lsd DerivativesBetterLife Pharma Inc. announced that its patent application for BETR-001 and LSD derivatives titled “LSD derivatives, synthesis & method for treatment of diseases and disorders” has been published by the United States Patent and Trademark Office under publication number US-2023/0357243-A1 and available for access on USPTO’s databases. BetterLife is presently developing one of these derivatives: a 2-bromo derivative of LSD (BETR-001) that is non-hallucinogenic and, in preclinical animal models, has been shown to be a potent neuroplastogen and have efficacy against depression/anxiety states. This published U.S. patent is part of a developing international patent portfolio which cover new compositions of 2-bromo-LSD and other LSD derivatives. In addition to composition claims, these applications also cover a novel method for making non-hallucinogenic LSD derivatives that does not involve the use of controlled substances at any stage. The applications also cover use of these derivatives in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and neuropathic pain. Betterlife is also pleased that its efforts to develop novel therapies for mental disorders were highlighted in the November 8 edition of The Atlantic. The Atlantic journal highlighted the potential of the BETR-001 program, as a non-hallucinogenic analog of LSD, in an article entitled “What If Psychedelics’ Hallucinations Are Just a Side Effect?” The article discusses, in part, that a growing number of key opinion leaders in neuroscience now believe that the hallucination caused by psychedelics is just a side effect and not necessary to produce mental-health benefits by this class of drugs. BETR-001 is currently undergoing IND-enabling studies and projected to enter human trials in 2024.お知らせ • Jul 14BetterLife Pharma Inc. announced that it has received CAD 0.22 million in fundingBetterLife Pharma Inc. announced a non-brokered private placement of 2,200,000 units at a price of CAD 0.10 per non-brokered unit for aggregate gross proceeds of CAD 220,000 on July 13, 2023. Each non-brokered unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.15 at any time up of 60 months from the closing of the offering. The units sold pursuant to the offering will be subject to a four month hold period pursuant to applicable Canadian securities laws.お知らせ • Jun 23BetterLife Pharma Inc. Announces Appointment of Steven Sangha as Corporate Development AdvisorBetterLife Pharma Inc. announced the appointment of Dr. Steven Sangha as corporate development advisor to the Company. Dr. Sangha has over 25 years of experience in investment banking, business development and asset management. His extensive experience with public company governance and compliance, and finance has led him to successfully run a Private Fund Family Office. Dr. Sangha’s interest in the biotechnology industry has allowed positive growth for early-stage companies with his consummate efforts in assessment, development and financial support. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.お知らせ • Jun 09BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling StudiesBetterLife Pharma Inc. announced that the IND-enabling studies BetterLife's 2-bromo-LSD ("BETR -001") continue to progress. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide ("LSD") derivative molecule. BetterLife has previously completed the preclinical pharmacological profiling of BETR-001, which showed that BETR-001 has robust activity in various depression/an anxiety animal models without hallucinogenic activity. The BETR-001 IND-enabling animal toxicology studies are now in various stages of completion. The in-life portion of the 28-day repeat dose GLP toxicology study in dogs has now been completed, and the histopathological analyses are ongoing. The GMP manufacturing of BETR-001 drug substance is also in its final stages.株主還元BETR.FUS PharmaceuticalsUS 市場7D-7.0%5.0%1.1%1Y-43.7%44.3%28.7%株主還元を見る業界別リターン: BETR.F過去 1 年間で44.3 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: BETR.Fは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is BETR.F's price volatile compared to industry and market?BETR.F volatilityBETR.F Average Weekly Movement28.4%Pharmaceuticals Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: BETR.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: BETR.Fの weekly volatility ( 28% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2002n/aAhmad Doroudianwww.abetterlifepharma.comバイオテクノロジー企業であるBetterLife Pharma Inc.は、主にカナダで精神障害治療用化合物の開発に注力している。また、ウイルス感染と闘うために免疫系に働きかける可能性のある、インターフェロンをベースとした一連の補完的技術から薬剤候補を精製・開発することにも携わっている。同社の製品パイプラインには、大うつ病性障害、不安神経症、神経因性疼痛、その他の神経精神疾患および神経疾患の治療薬BETR-001、ベンゾジアゼピン依存症、不安神経症、神経変性疾患の治療薬BETR-002がある。また、COVID-19をはじめとする呼吸器系ウイルス感染症の治療薬として第II相臨床試験を完了したMM-003、HPVによる子宮頸部上皮内新形成の治療薬として膣内局所の第II相臨床試験を完了した局所用クリームMM-001の開発も進めている。同社は以前Pivot Pharmaceuticals Inc.として知られていたが、2019年12月にBetterLife Pharma Inc.に社名を変更した。BetterLife Pharma Inc.は2002年に法人化され、カナダのバンクーバーに本社を置いている。もっと見るBetterLife Pharma Inc. 基礎のまとめBetterLife Pharma の収益と売上を時価総額と比較するとどうか。BETR.F 基礎統計学時価総額US$7.37m収益（TTM）-US$1.34m売上高(TTM)n/a0.0xP/Sレシオ-5.5xPER（株価収益率BETR.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BETR.F 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$1.85m収益-CA$1.85m直近の収益報告Oct 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.011グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-12.3%BETR.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 15:14終値2026/05/21 00:00収益2025/10/31年間収益2025/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BetterLife Pharma Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 18BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in fundingOn April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering.
お知らせ • Apr 09BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in fundingBetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws.
お知らせ • May 28Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026.
お知らせ • May 19BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025.
お知らせ • May 15BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric DisordersBetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases.
お知らせ • Mar 31BetterLife Pharma Inc. Appoints Steven Sangha to its Board of DirectorsBetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.
お知らせ • Apr 18BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in fundingOn April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering.
お知らせ • Apr 09BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in fundingBetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws.
お知らせ • May 28Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026.
お知らせ • May 19BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025.
お知らせ • May 15BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric DisordersBetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases.
お知らせ • Mar 31BetterLife Pharma Inc. Appoints Steven Sangha to its Board of DirectorsBetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.
お知らせ • Nov 27BetterLife Pharma Inc. Obtains Cardiac Safety Data for BETR-001BetterLife Pharma Inc. announced it has completed one of its IND-enabling cardiac safety studies of BETR-001. These GLP in vitro studies demonstrated that BETR-001 has minimal impact on the human ether- a-go-go-related gene (hERG) channel, an important ion channel for cardiac functioning.
お知らせ • Oct 23BetterLife Pharma Inc. Obtains Favourable Genotoxicity Data for Oral BETR-001BetterLife Pharma Inc. announced it has completed one of its IND-enabling genotoxicity studies of BETR-001. The studies demonstrated that oral BETR-001, even at very high doses, does not show any evidence of bone marrow toxicity or mutagenic (DNA mutation) and clastogenic (chromosome damage) activities. The GLP genotoxicity studies conducted on BETR-001 included in vitro bacterial reverse mutation assay, in vitro micronucleus test, and in vivo micronucleus test in male and female rats. These studies are a critical component of the safety assessment required by the U.S. Food and Drug Administration (FDA) and needed for entry into clinical trials.
お知らせ • Aug 29BetterLife Pharma Inc. announced that it expects to receive CAD 1.1 million in fundingBetterLife Pharma Inc announced a non brokered private placement offering of 7,333,333 units issued at a price of CAD 0.15 per unit for gross proceeds CAD 1,099,999.95 on August 29, 2024. Each unit consisting of one common share in the capital of the Company and one full common share purchase warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD 0.20 for up to two years following the date of the closing of the Private Placement. The close is subject to the receipt of all necessary regulatory and other approvals which will be announced as soon as it has been completed.
お知らせ • Jul 03BetterLife Pharma Inc. announced that it has received CAD 0.175 million in fundingOn July 2, 2024, BetterLife Pharma Inc. closed the transaction.
お知らせ • May 15BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001BetterLife Pharma Inc. announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials did not show any significant cardiopulmonary pharmacological safety issues in animals. Cardiopulmonary safety (also known as telemetry) studies investigate the effect of a drug in animals using surgically implanted transmitters to assess blood pressure, electrocardiography (ECG), lung respiration, body temperature, and general activity level. The BETR-001 cardiopulmonary study found no BETR-001 related effects on ECG intervals, respiratory parameters, core body temperature, or activity levels.
お知らせ • May 03BetterLife Pharma Inc. Advances BETR-001 IND-Enabling StudiesBetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024.
お知らせ • Apr 13BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024.
お知らせ • Mar 05BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in fundingBetterLife Pharma Inc. announced a private placement to issue convertible debentures for the gross proceeds of CAD 100,000 on March 4, 2024. The transaction will include participation from individual investor such as Ahmad Doroudian for CAD 100,000.
お知らせ • Mar 04BetterLife Pharma Inc. announced that it has received CAD 0.065 million in fundingBetterLife Pharma Inc. announced a private placement to issue 10% convertible debentures for the gross proceeds of CAD 65,000 on March 4, 2024. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on August 31, 2026. The debentures bear 10% interest rate and matures on February 28, 2026.
お知らせ • Jan 02BetterLife Pharma Inc. announced that it has received CAD 0.3 million in fundingBetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 10% convertible debentures for principal[al amount of CAD 300,000 on January 2, 2024. The convertible debenture interest rate of 10%, will mature on June 30, 2025. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on December 31, 2025. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of CAD 125,000 principal amount of convertible debentures under the Offering.
お知らせ • Dec 18BetterLife Pharma Inc. announced that it has received CAD 0.2 million in fundingBetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 2,000,000 units at an issue price of CAD 0.10 per Unit for aggregate gross proceeds of CAD 200,000 on December 18, 2023. Each Unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.10 at any time up to 24 months from the closing of the Offering. The Units sold pursuant to the Offering will be subject to a four month hold period pursuant to applicable Canadian securities laws. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of 1,000,000 Units under the Offering.
お知らせ • Dec 01Us Patent and Trademark Office Publishes Betterlife’S Comprehensive Patent for Betr-001 and Other Lsd DerivativesBetterLife Pharma Inc. announced that its patent application for BETR-001 and LSD derivatives titled “LSD derivatives, synthesis & method for treatment of diseases and disorders” has been published by the United States Patent and Trademark Office under publication number US-2023/0357243-A1 and available for access on USPTO’s databases. BetterLife is presently developing one of these derivatives: a 2-bromo derivative of LSD (BETR-001) that is non-hallucinogenic and, in preclinical animal models, has been shown to be a potent neuroplastogen and have efficacy against depression/anxiety states. This published U.S. patent is part of a developing international patent portfolio which cover new compositions of 2-bromo-LSD and other LSD derivatives. In addition to composition claims, these applications also cover a novel method for making non-hallucinogenic LSD derivatives that does not involve the use of controlled substances at any stage. The applications also cover use of these derivatives in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and neuropathic pain. Betterlife is also pleased that its efforts to develop novel therapies for mental disorders were highlighted in the November 8 edition of The Atlantic. The Atlantic journal highlighted the potential of the BETR-001 program, as a non-hallucinogenic analog of LSD, in an article entitled “What If Psychedelics’ Hallucinations Are Just a Side Effect?” The article discusses, in part, that a growing number of key opinion leaders in neuroscience now believe that the hallucination caused by psychedelics is just a side effect and not necessary to produce mental-health benefits by this class of drugs. BETR-001 is currently undergoing IND-enabling studies and projected to enter human trials in 2024.
お知らせ • Jul 14BetterLife Pharma Inc. announced that it has received CAD 0.22 million in fundingBetterLife Pharma Inc. announced a non-brokered private placement of 2,200,000 units at a price of CAD 0.10 per non-brokered unit for aggregate gross proceeds of CAD 220,000 on July 13, 2023. Each non-brokered unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.15 at any time up of 60 months from the closing of the offering. The units sold pursuant to the offering will be subject to a four month hold period pursuant to applicable Canadian securities laws.
お知らせ • Jun 23BetterLife Pharma Inc. Announces Appointment of Steven Sangha as Corporate Development AdvisorBetterLife Pharma Inc. announced the appointment of Dr. Steven Sangha as corporate development advisor to the Company. Dr. Sangha has over 25 years of experience in investment banking, business development and asset management. His extensive experience with public company governance and compliance, and finance has led him to successfully run a Private Fund Family Office. Dr. Sangha’s interest in the biotechnology industry has allowed positive growth for early-stage companies with his consummate efforts in assessment, development and financial support. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia.
お知らせ • Jun 09BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling StudiesBetterLife Pharma Inc. announced that the IND-enabling studies BetterLife's 2-bromo-LSD ("BETR -001") continue to progress. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide ("LSD") derivative molecule. BetterLife has previously completed the preclinical pharmacological profiling of BETR-001, which showed that BETR-001 has robust activity in various depression/an anxiety animal models without hallucinogenic activity. The BETR-001 IND-enabling animal toxicology studies are now in various stages of completion. The in-life portion of the 28-day repeat dose GLP toxicology study in dogs has now been completed, and the histopathological analyses are ongoing. The GMP manufacturing of BETR-001 drug substance is also in its final stages.
